|
|
|
| Comparison of Effects of Docetaxel Alone and Its Combination with Thiotepa in the Treatment of Metastatic Breast cancer |
| LI Ai-feng |
| Department of Internal Medicine, People's Hospital of Lianshui County, Jiangsu 223400 |
|
|
|
|
Abstract 【Objective】To study the effects and prognosis of docetaxel alone and its combination with thiotepa in the treatment of metastatic breast cancer(MBC). 【Methods】A total of 86 patients with MBC were divided into the docetaxel treatment group (group A,n=42) and docetaxel combined with thiotepa group (group B,n=44). The short-term curative effect, adverse reactions and survival rate were compared between the two groups. 【Results】The effective rate of treatment and clinical control rate in group A were 50% and 80.95%, respectively, while those in group B were 56.82% and 90.91%, respectively; the differences were not statistically significant (P>0.05). The neutropenia, anemia, thrombocytopenia and adverse reactions in group B were more serious than those in group A; and the differences were statistically significant (P<0.05). The progression-free survival time was 12.64 months in group A and 14.26 months in group B. There was no significant difference between the two groups (P>0.05). The 1-year, 2-year and 3-year local control rates of tumor and survival rates were 42.8%, 19.05%, 2.38% and 47.62%, 21.43%, 4.76% in group A, while those in group B were 50%, 22.73%, 11.36% and 54.55%, 31.82%, 15.91%. The 3-year survival rate showed significant difference (P<0.05). There was no significant difference in the rate of tumor control and survival between the two groups at 1 year and 2 years (P>0.05), but the 3-year survival rate in group A was lower than that in group B, and the difference was significant (P<0.05). 【Conclusion】The short-term and long-term effects of docetaxel alone and its combination with thiotepa are similar in the treatment of metastatic breast cancer. Although the toxicity of docetaxel alone is smaller, its 3-year survival rate is lower than that of the combination group. The specific chemotherapy should be chosen according to the actual condition of patients.
|
|
Received: 21 November 2016
|
|
|
|
|
|
[1] 何小艳,李慧,刘倩,等.乳腺癌HER-2检测方法比价及其与ER、PR、淋巴结转移的相关性分析[J].医学临床研究,2016,33(9):1740-1743.
[2] 李学瑞,张国淳,姚濛,等.以紫杉醇为基础的化疗在三阴性乳腺癌新辅助治疗中的疗效和安全性评价[J].国际医药卫生导报,2011,17(16):1944-1947.
[3] 周心娜,董宁宁,余靖,等.CYP3A5和GSTP1基因多态性与多西他赛联合塞替派治疗转移性乳腺癌近期疗效的相关性研究[J].中国药学杂志,2012,47(2):127-131.
[4] 章国晶,郭放,谢晓冬.2012版美国国立综合癌症网络乳腺癌指南更新要点及研究进展荟萃[J].中国实用内科杂志,2013,33(2):127-130.
[5] Therasse P,鄢践,曾益新.实体瘤疗效评定最新指南[J].国际肿瘤学杂志,2000,27(6):375.
[6] 邵彬,李惠平,邸立军,等.多西他赛单药与联合方案一线治疗转移性乳腺癌的疗效及预后相关因素分析[J].肿瘤,2016,36(6):683-691.
[7] Bonneterre J, Roché H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure[J]. Br J Cancer,2011,87(11):1210-1215.
[8] Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer.[J]. Cochrane Database Syst Rev,2009,15(2):CD003372. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(6): 1201-1202. |
|
|
|
|
2018, Vol. 35 
